Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in <i> BRAF <sup>V600E</sup> </i> -Mutated Anaplastic Thyroid CarcinomaJennifer Wang, Maria E. Cabanillas, Mark Zafereo et al.|Thyroid|2019Cited by 229
Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF <sup>V600E</sup> -Mutated Anaplastic Thyroid CarcinomaSarah Hamidi, Maria E. Cabanillas, Ramona Dadu et al.|Thyroid|2024Cited by 72
Initial Management of <i>BRAF </i>V600E-Variant Anaplastic Thyroid CancerSarah Hamidi, Maria E. Cabanillas, Ramona Dadu et al.|JAMA Oncology|2024Cited by 35
<i>NTRK</i> Fusion–Positive Thyroid Carcinoma: From Diagnosis to Targeted TherapyVicente Rodrigues Marczyk, Maria E. Cabanillas, Sasan Fazeli et al.|JCO Precision Oncology|2025Cited by 10
Adjuvant Pembrolizumab after Upfront Multimodal Therapy for Stage IVB Anaplastic Thyroid CancerMaria E. Cabanillas, Naifa L. Busaidy, G. Brandon Gunn et al.|Thyroid|2025Cited by 8